Q1 2024

Filed May 15, 2024 · 10-Q · 45 days after period end · 0001477932-24-002923

Q1 2024 · 10-Q

Revenue

$3.62K

−91.0% vs Q1 2023

Net Income

-$1.24M

N/M vs Q1 2023

EPS, diluted—

Operating Income-$968,692N/M

Operating Cash Flow-$339,668N/M

Same quarter

Metric	Q1 2024	Q1 2023	Q1 2022	Q1 2021
Revenue	$3.62K	$40.44K	$20.52K	$10.12K
Net Income	-$1.24M	-$1.01M	-$944.99K	-$1.58M
EPS Diluted	—	—	—	-$0.26

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR